ClinicalTrials.gg
RecruitingNCT05516667ALFA3pilotUpdated Dec 19, 2024

Cohort of Patients with Alzheimer's Disease and Their Families.

An observational study in Alzheimer Disease, sponsored by University Hospital, Toulouse. Recruiting at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alzheimer Disease by University Hospital, Toulouse — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University Hospital, Toulouse.

Started
2023
the only one that year
Observational
3 of 17
1 open now
Registered
15th of 17
by date

Among the 17 studies in Alzheimer Disease by University Hospital, Toulouse, this one is the only one that started in 2023, is one of 3 observational ones, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 17 studies in Alzheimer Disease by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

This is the pilot phase of a longitudinal observational cohort study. The study includes family clusters comprised of a patient with Alzheimer's disease, an informal caregiver and at least one first-degree relative of the patient. The family clusters will be followed-up in expert memory centers and online in order to study risk and prognostic factors (including blood-based biomarkers) in the first-degree relatives and patients, respectively, as well as caregiver health, difficulties and needs. This pilot study is performed to assess the feasibility of conducting a larger-scale study.

Read the detailed description

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the primary cause of dementia. It brings about a huge burden for patients, families and society as a whole. There is currently no curative treatment available, but the existence of a long preclinical period, during which biomarker changes are observed, and the identification of modifiable risk factors suggest that AD may be preventable. Data is currently lacking, however, on the trajectories and predictive value of blood-based biomarkers (which are more acceptable and less costly to measure than traditional imaging and Cerebrospinal fluid biomarkers biomarkers). Furthermore, although there has been much research into modifiable AD risk factors, they have often not been studied simultaneously in the same cohort, and there has been relatively little research into newly identified risk factors, such as hearing impairment. First-degree relatives of AD patients would seem an ideal population to study such factors, since they are at increased risk of dementia and cognitive decline, and may be more motivated to participate in dementia research studies than other individuals. Finally, although caregiver burden and quality of life have been previously studied, further data is required on their longitudinal trajectories, particularly taking into account the disease course of the patients they care for. Caregivers' needs and coping and caregiving strategies also need to be better understood. In the pilot phase of the ALFA3 study, 150 familial clusters (each comprised of a patient with Alzheimer's disease, a family caregiver and at least one first-degree relative of the patient) will be recruited and followed-up for 2 years in expert memory centers and via online questionnaires. This pilot phase will be used to study the feasibility of conducting a larger-scale study.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • dementia
  • caregivers
  • risk factors
  • prognosis
  • first-degree relatives
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

3 types of participants : patients with AD, caregivers assisting such patients on daily activities, and close relatives as defined above

Eligibility criteria

o Inclusion criteria:

AD patients:

  • Probable Alzheimer's disease (clinical and biological NINCDS-ADRDA 2011 criteria)
  • Mild-moderate AD ( ≥15)
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to undergo medical examinations at baseline, 12 and 24 months, as outlined in the protocol
  • Affiliated to French social security
  • Written

Caregivers:

  • Caregiver (defined as assisting the patient in activities of daily living for at least 6 hours per week during the last 6 months) to an AD patient having agreed to participate in the study
  • Age ≥18 years.
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to answer regular questionnaires about their own or the AD patient's health (during visits at study centres or via a secure internet website/postal questionnaires)
  • Affiliated to French social security
  • Written informed consent

First-degree relatives:

  • First degree relative of an AD patient having agreed to participate in the study
  • Age ≥18 years.
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to undergo medical examinations at baseline, 12 and 24 months, as outlined in the protocol
  • Agrees to answer regular questionnaires about their own health (via a secure internet website or via postal questionnaires)
  • Affiliated to French social security
  • Written informed consent

In order to be included in the study, a familial cluster must be comprised of 2 to 5 people, as follows:

  • Familial cluster of 2 people: 1 AD patient and 1 first-degree relative who also meets the caregiver inclusion criteria, OR
  • Familial cluster of 3 to 5 people: 1 AD patient, 1 caregiver (does not need to be a relative of the patient), 1 to 3 first-degree relatives of the patient

    • Exclusion criteria:

AD patients:

  • Other brain disorders
  • Autosomal dominant form of AD
  • Under legal protection measure (guardianship, curators, safeguard of justice...)
  • Institutionalized
  • \<2 years

Caregivers:

  • Under legal protection measure (guardianship, curators, safeguard of justice...)
  • Diagnosed with a major neurocognitive disorder

First-degree relatives:

  • Related to a patient with an autosomal dominant form of dementia
  • Carrier of an autosomal dominant dementia mutation
  • Under legal protection measure (guardianship, curators, safeguard of justice...)
  • Diagnosed with a major neurocognitive disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Recruitment rate

    rate of actual inclusion on anticipated inclusion 9 months and 18-months after the first inclusion. Expressed in percentage

    Time frame: 18-months after the first inclusion

  2. Retention rate

    rate of remaining participants on actual inclusions 24 months after the first subject was included. Expressed in percentage

    Time frame: 24 months after the first inclusion

Secondary outcomes

  1. Cognitive function

    Evolution of the Mini Mental State Examination score : from Baseline to the end of follow-up. The scores can vary from 0 to 30; 0 being the lowest cognitive function and 30 representing "non pathological" functioning.

    Time frame: 60 months after Baseline

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 37 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Apr 6, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jan 1, 2027
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05516667
Collaborators
France Alzheimer
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Apr 6, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Dec 19, 2024

Study contacts

Sandrine Andrieu, MD PhD
Contact
sandrine.andrieu@univ-tlse3.fr
05 61 14 59 63
Nicola Coley, PhD
Contact
coley.n@chu-toulouse.fr
Sandrine Andrieu, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion